<?xml version="1.0" encoding="UTF-8"?>
<p>BCG-CORONA (Reducing Health Care Workers Absenteeism in COVID-19 Pandemic Through BCG Vaccine) trial is expected to enrol 1,500 healthcare workers exposed to the virus within the coming 6 months and randomize them into BCG intradermal vaccination and placebo groups; number of days of unplanned absenteeism for any reason is primary outcome of the trial.
 <xref rid="B25" ref-type="bibr">25</xref> BRACE trial (BCG Vaccination to Protect Healthcare Workers Against COVID-19) is set to enrol 4,170 participants, randomize them into intervention and no intervention groups, and record COVID-19 incidence and its severe course in the 12 months following randomization.
 <xref rid="B26" ref-type="bibr">26</xref> These studies testing the effects of the nonspecific vaccination on the course of COVID-19 in adults may raise serious ethical concerns due to the risks of exposing vaccinated and non-vaccinated to the virus.
</p>
